Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EarLEE-1: Ribociclib + ET in High Risk Early Breast Cancer
NCT03078751Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ribociclib in breast cancer, sponsored by Novartis. Started Jun 2017; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03078751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03078751.